We are sorry. The requested page has been moved or was not found.
Please see full Prescribing Information for Ranexa.
You are now leaving RanexaHCP.com.
You are now leaving the Ranexa website. Gilead Sciences, Inc. provides these links as a convenience; however, Gilead does not control, review, or endorse third-party websites, and is not responsible for the content of the website you are about to enter.
Before viewing TERISA clinical data, please review key information from the pivotal Phase 3 CARISA trial, which established the efficacy of Ranexa® in treating chronic angina.
Limit the dose of Ranexa to 500 mg BID when coadministered with diltiazem, verapamil, or other moderate CYP3A inhibitors.
BID=twice a day.